Dosage regime of crinecerfont for treating congenital adrenal hyperplasia
AssigneeNeurocrine Biosciences, Inc.
InventorsJean L. Chan, Robert H. Farber
Life of this patent
Estimating the term…
Abstract
Provided are methods of administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in an adult subject having congenital adrenal hyperplasia.
Claims53
A method of administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof,
- as an adjunct to glucocorticoid therapy in an adult subject having congenital adrenal hyperplasia (CAH), said method comprising:
- administering to the subject a first amount of Compound A, or a pharmaceutically acceptable salt thereof, for a first period of time, and subsequently administering to the subject a second amount of Compound A, or a pharmaceutically acceptable salt thereof, for a second period of time, wherein the second amount is equivalent to about 200 mg of Compound A free base q.P.M, and wherein the first amount of Compound A is a missed dose.
-30. (canceled)
A method of administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine,
- as an adjunct to glucocorticoid therapy in an adult subject having congenital adrenal hyperplasia (CAH), said method comprising:
- administering to the subject a first amount of Compound A for a first period of time, and subsequently administering to the subject a second amount of Compound A for a second period of time, wherein the second amount is equivalent to about 200 mg of Compound A free base q.P.M, and wherein the first amount of Compound A is a missed dose.
A method of treating classic congenital adrenal hyperplasia in a subject in need thereof wherein said subject is administered twice daily a dose of Compound A:
- or a pharmaceutically acceptable salt thereof,
- and wherein the subject has missed a dose of Compound A, comprising:
- administering to the subject the amount of the missed dose of Compound A, and resuming the twice daily administration of Compound A, or a pharmaceutically acceptable salt thereof.
A method of treating classic congenital adrenal hyperplasia in a subject in need thereof wherein said subject is administered twice daily a dose of Compound A:
- and wherein the subject has missed a dose of Compound A, comprising:
- administering to the subject the amount of the missed dose of Compound A as soon as possible and
- resuming the twice daily administration of Compound A.
Dependencies are inferred from the claim text.